The clinical efficacy and safety of four- weekly docetaxel as first-line therapy in elderly lung cancer patients with squamous cell carcinoma

Jong Hyun Choi, Juwhan Choi, Sang Mi Chung, Jee Youn Oh, Young Seok Lee, Kyung Hoon Min, Gyu Young Hur, Jae Jeong Shim, Kyung Ho Kang, Hyun Kyung Lee, Sung Yong Lee

Research output: Contribution to journalArticle


Background: Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase II clinical study, we investigated the efficacy and safety of a 4-weekly schedule of docetaxel monotherapy, as first-line chemotherapy for advanced squamous cell carcinoma in elderly lung cancer patients. Methods: Patients with stage IIIB/ IV lung squamous-cell carcinoma age 70 or older, that had not undergone cytotoxic chemotherapy were enrolled. Patients received docetaxel 25 mg/m2 on days 1, 8, and 15, every 4 weeks. Primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity profiles. Results: A total of 19 patients were enrolled. Among 19 patients, 17 were for evaluated efficacy and safety. In the intentto- treat population, ORR and disease control rate (DCR) were 11.8% and 47.1%, respectively. In the response evaluable population, ORR was 16.7% and DCR was 66.7%. Median PFS and OS were 3.1 months and 3.3 months, respectively. There were three adverse grade 3/4 events. Grade 1 neutropenia was reported in one patient. Conclusion: Our data failed to demonstrate efficacy of a 4-weekly docetaxel regimen, in elderly patients with a poor performance status. However, incidence of side effects, including neutropenia, was lower than with a 3-week docetaxel regimen, as previously reported.

Original languageEnglish
Pages (from-to)211-216
Number of pages6
JournalTuberculosis and Respiratory Diseases
Issue number3
Publication statusPublished - 2019 Jan 1


  • Aged
  • Carcinoma
  • Carcinoma
  • Chemotherapy
  • Docetaxel
  • Lung Neoplasms
  • Non-Small-Cell Lung
  • Safety
  • Squamous Cell
  • Therapeutics
  • Treatment Outcome

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this